ADP-520
CD70-expressing cancers (hematological malignancies, AML, lymphoma, RCC)
Indication EnablingIn progress
Key Facts
Indication
CD70-expressing cancers (hematological malignancies, AML, lymphoma, RCC)
Phase
Indication Enabling
Status
In progress
Company
About Adaptimmune Therapeutics
Adaptimmune's mission is to develop novel, engineered TCR T-cell therapies capable of targeting a broad range of solid tumors by recognizing intracellular cancer proteins. Its key achievement was advancing multiple assets into late-stage trials before executing a strategic transformation in 2025, selling its lead clinical programs (including afami-cel and lete-cel) to US WorldMeds, delisting from Nasdaq, and restructuring its leadership. The company's current strategy is to maximize value from its remaining earlier-stage pipeline targeting PRAME and CD70, while significantly reducing operational and public company costs as a streamlined, OTC-quoted entity.
View full company profile